Health

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for COVID-19 Vaccine (mRNA-1273)

CAMBRIDGE, Mass .– (COMMERCIAL WIRE) – Moderna, Inc. (Nasdaq: MRNA), a biotech company pioneering clinical messenger RNA (mRNA) therapies and vaccines to create a new generation of transforming drugs for patients, today announced a modification to its contract with Biomedical Advanced Research and the Development Authority (BARDA) for an additional …

Read More »